ANIP - ANI Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ANIP is currently covered by 5 analysts with an average price target of $87.97. This is a potential upside of $16.44 (22.98%) from yesterday's end of day stock price of $71.53.

ANI Pharmaceuticals's activity chart (see below) currently has 50 price targets and 63 ratings on display. The stock rating distribution of ANIP is 10.34% HOLD and 89.66% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 79.54% with an average time for these price targets to be met of 338.13 days.

Highest price target for ANIP is $94, Lowest price target is $62, average price target is $81.25.

Most recent stock forecast was given by VAMIL DIVAN from GUGGENHEIM on 11-Apr-2025. First documented stock forecast 15-Dec-2014.

Currently out of the existing stock ratings of ANIP, 3 are a HOLD (10.34%), 26 are a BUY (89.66%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$86

$13.05 (17.89%)

$86

28 days ago
(11-Apr-2025)

6/9 (66.67%)

$17.88 (26.25%)

343

Buy

$94

$21.05 (28.86%)

$94

1 months 22 days ago
(17-Mar-2025)

4/13 (30.77%)

$29.65 (46.08%)

148

Hold

$62

$-10.95 (-15.01%)

$60

6 months 17 days ago
(22-Oct-2024)

8/9 (88.89%)

$1.92 (3.20%)

396

Buy

$83

$10.05 (13.78%)

$49

7 months 21 days ago
(18-Sep-2024)

10/12 (83.33%)

$21.95 (35.95%)

474

Hold

$42

$-30.95 (-42.43%)

$40

2 years 1 days ago
(08-May-2023)

2/3 (66.67%)

$-0.58 (-1.36%)

274

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ANIP (ANI Pharmaceuticals) average time for price targets to be met?

On average it took 338.13 days on average for the stock forecasts to be realized with a an average price target met ratio 79.54

Which analyst has the current highest performing score on ANIP (ANI Pharmaceuticals) with a proven track record?

LOUISE CHEN

Which analyst has the current lower performing score on ANIP (ANI Pharmaceuticals) with a proven track record?

BRANDON FOLKES

Which analyst has the most public recommendations on ANIP (ANI Pharmaceuticals)?

Louise Chen works at SCOTIABANK and has 9 price targets and 5 ratings on ANIP

Which analyst is the currently most bullish on ANIP (ANI Pharmaceuticals)?

Oren Livnat with highest potential upside - $21.05

Which analyst is the currently most reserved on ANIP (ANI Pharmaceuticals)?

Brandon Folkes with lowest potential downside - -$30.95

ANI Pharmaceuticals in the News

ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 millionRecord Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered...

Pacira (PCRX) Q1 Earnings Surpass Estimates

Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8.77%. A quarter ago, it was expected that this...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?